Cargando…

The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective

Over the past decade, the development of high-efficacy disease-modifying therapies (DMTs) has been responsible for more effective management of relapsing-remitting multiple sclerosis (RRMS). However, the gaps in optimal care for this complex disease remain. Alemtuzumab (Lemtrada®) is a highly effica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alroughani, Raed, Van Wijmeersch, Bart, Al Khaboori, Jabber, Alsharoqi, Isa Ahmed, Ahmed, Samar F., Hassan, Ali, Inshasi, Jihad, Krieger, Derk W., Shakra, Mustafa, Shatila, Ahmed Osman, Szolics, Miklos, Khallaf, Mohamed, Ezzat, Aly
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498833/ https://www.ncbi.nlm.nih.gov/pubmed/32973927 http://dx.doi.org/10.1177/1756286420954119

Ejemplares similares

Multicentre Observational Study of Treatment Satisfaction with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in the Arabian Gulf: The CLUE Study
por: Inshasi, Jihad, et al.
Publicado: (2023)

An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion
por: Alroughani, Raed, et al.
Publicado: (2019)

Disease-Modifying Drugs and Family Planning in People with Multiple Sclerosis: A Consensus Narrative Review from the Gulf Region
por: Alroughani, Raed, et al.
Publicado: (2020)

Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates
por: Inshasi, Jihad S., et al.
Publicado: (2021)

Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: An expert consensus narrative review
por: Alroughani, Raed, et al.
Publicado: (2022)

Expert Consensus and Narrative Review on the Management of Multiple Sclerosis in the Arabian Gulf in the COVID-19 Era: Focus on Disease-Modifying Therapies and Vaccination Against COVID-19
por: Inshasi, Jihad, et al.
Publicado: (2021)

Neuromyelitis optica spectrum disorders in the Arabian Gulf: challenges and growing experience
por: Alroughani, Raed, et al.
Publicado: (2020)

Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? A Narrative Review
por: AlSharoqi, Isa Ahmed, et al.
Publicado: (2020)

Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East
por: Alroughani, Raed, et al.
Publicado: (2022)

Incidence, Severity, Outcomes, and Risk Factors of COVID-19 in Multiple Sclerosis: An Observational Study in the Middle East
por: Alroughani, Raed, et al.
Publicado: (2022)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Future of Management of Multiple Sclerosis in the Middle East: A Consensus View from Specialists in Ten Countries
por: Aljumah, Mohammed, et al.
Publicado: (2013)

Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis
por: Graves, Jennifer, et al.
Publicado: (2013)

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS
por: Thomas, Katja, et al.
Publicado: (2016)

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Real-world experience on the use of COVID-19 vaccination in patients with multiple sclerosis treated with Cladribine tablets in the Gulf region
por: Inshasi, Jihad, et al.
Publicado: (2022)

Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East
por: Achiron, Anat, et al.
Publicado: (2017)

Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
por: Guarnera, Cristina, et al.
Publicado: (2017)

Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
por: Alroughani, R., et al.
Publicado: (2013)

Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence
por: Alroughani, Raed, et al.
Publicado: (2017)

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies
por: Comi, Giancarlo, et al.
Publicado: (2019)

Multiple sclerosis in the Arabian Gulf countries: a consensus statement
por: Bohlega, Saeed, et al.
Publicado: (2013)

Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?
por: Alroughani, Raed, et al.
Publicado: (2016)

Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis
por: Gilmore, Wendy, et al.
Publicado: (2020)

Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis
por: Kashani, Nicole, et al.
Publicado: (2021)

Burden of migraine in a Kuwaiti population: a door-to-door survey
por: Al-Hashel, Jasem Yousef, et al.
Publicado: (2017)

Prevalence and Burden of Primary Headache Disorders in Kuwaiti Children and Adolescents: A Community Based Study
por: Al-Hashel, Jasem Yousef, et al.
Publicado: (2019)

Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis
por: Behbehani, Raed, et al.
Publicado: (2017)

Impact of the first Gulf war on multiple sclerosis risk in Kuwait: a quasi-experimental study
por: Akhtar, Saeed, et al.
Publicado: (2023)

Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks
por: Alroughani, Raed, et al.
Publicado: (2016)

Status migrainosus as an initial presentation of multiple sclerosis
por: Alroughani, Raed, et al.
Publicado: (2015)

Economic burden of multiple sclerosis on Kuwait health care system
por: Alowayesh, Maryam S., et al.
Publicado: (2019)

Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care
por: Salama, Sara, et al.
Publicado: (2020)

MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis
por: Yamout, Bassem I, et al.
Publicado: (2021)

Spinal segmental myoclonus as an unusual presentation of multiple sclerosis
por: Alroughani, Raed Abdullah, et al.
Publicado: (2015)

Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
por: Van Wijmeersch, Bart, et al.
Publicado: (2019)

A case report of multiple sclerosis after COVID-19 infection: causality or coincidence?
por: Ismail, Ismail Ibrahim, et al.
Publicado: (2021)

Association of Multiple Sclerosis and COVID-19 Infection: A Case Report
por: Ismail, Ismail Ibrahim, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_te5qsnee4tttjr6ec6roaes7vq